A Randomized, Multicenter, Phase 3 Study of Zanidatamab in Combination With Chemotherapy With or Without Tislelizumab in Subjects With HER2-positive Unresectable Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma (GEA) (HERIZON-GEA-01)
HER2-positive Unresectable Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma
Pantai Hospital Kuala Lumpur
PRINCIPAL INVESTIGATOR
DR LAM KAI SENG
drkslam@gmail.com
CONTACT
General Line: 03 – 2296 0888
CRC: 03 – 2280 1320 / 2280 1321 / 2280 1322
Hospital Pulau Pinang
PRINCIPAL INVESTIGATOR
DR FONG CHIN HENG
fongchinheng@gmail.com
CONTACT
General line: 04-2225 333
CRC: 042225 767 / 2225 762 / 2225 766 / 2225 586
Dr. Yoon Chee Kin, Ketua Jabatan
dryoonck@moh.gov.my (email)
Sister Zarina Bt Che Umar, Admin Manager
zarinacu@gmail.com (Email)
Sarawak General Hospital
PRINCIPAL INVESTIGATOR
VOON PEI JYE
CONTACT
Fong Yian Ching
General line: 082 – 276666
CRC: 082-276820 (Tel)
082-276823 (Fax)
Tiong Lee Len, Admin Manager
leelen.crc@gmail.com (Email)
(Facebook)
National Cancer Institute (IKN)
PRINCIPAL INVESTIGATOR
NORHIDAYU BT SALIMIN
CONTACT
SC: Shamiza Ahmad
General line : 03 – 8892 5555
CRC: 03 – 8892 5555 Ext 5418 (Tel)
03- 8892 5622 (Fax)